UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2021.

Commission File Number: 001-40530

GH Research PLC

(Exact name of registrant as specified in its charter)

28 Baggot Street Lower
Dublin 2
D02 NX43
Ireland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GH Research PLC

Date: December 6, 2021

By: /s/ Julie Ryan
Name: Julie Ryan
Title: Group Finance Director

EXHIBIT INDEX

Exhibit No.	Description
99.1	Unaudited Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2021
99.2	Management's Discussion and Analysis of Financial Condition and Results of Operations
99.3	Press release dated December 6, 2021

Exhibit 99.1

UNAUDITED CONDENSED CONSOLIDATED
INTERIM FINANCIAL STATEMENTS FOR THE
THREE AND NINE MONTHS ENDED
SEPTEMBER 30, 2021

GH RESEARCH PLC

Condensed consolidated interim statement of comprehensive income

	Note	Three months ended September 30, 2021 $'000	Three months ended September 30, 2020 $'000	Nine months ended September 30, 2021 $'000	Nine months ended September 30, 2020 $'000
Operating expenses					
Research and development		(2,556)	(55)	(5,202)	(105)
General and administration		(2,110)	(5)	(3,277)	(16)
Loss from operations		**(4,666)**	**(60)**	**(8,479)**	**(121)**
Finance expense		(3)	-	(9)	-
Foreign currency translation differences		2,832	-	3,377	-
Loss for the period		**(1,837)**	**(60)**	**(5,111)**	**(121)**
Other comprehensive income/(expense)					
Items that may be reclassified to profit or loss					
Currency translation adjustment		(2,845)	15	(3,533)	15
Total comprehensive loss for the period		**(4,682)**	**(45)**	**(8,644)**	**(106)**
Attributable to owners:					
Loss for the period		(1,837)	(60)	(5,111)	(121)
Comprehensive loss for the period		(2,845)	15	(3,533)	15
Loss per share					
Basic and diluted loss per share (in USD)	12	(0.035)	(0.002)	(0.125)	(0.004)

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

GH RESEARCH PLC

Condensed consolidated interim statement of financial position

	Note	At September 30, 2021 $'000	At December 31, 2020 $'000
ASSETS			
Current assets			
Cash		280,745	5,895
Other current assets	5	4,816	17
Total current assets		**285,561**	**5,912**
Non-current assets			
Property, plant and equipment		73	-
Total non-current assets		**73**	-
Total assets		**285,634**	**5,912**
LIABILITIES AND EQUITY			
Current liabilities			
Trade payables	6	1,214	1
Other current liabilities	7	819	245
Total current liabilities		**2,033**	**246**
Total liabilities		**2,033**	**246**
Equity attributable to owners			
Share capital	8	1,301	871
Share premium	8	291,448	5,430
Other reserves		131	-
Foreign currency translation reserve		(3,333)	200
Accumulated deficit		(5,946)	(835)
Total equity		**283,601**	**5,666**
Total liabilities and equity		**285,634**	**5,912**

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

GH RESEARCH PLC

Condensed consolidated interim statement of changes in equity

	Attributable to owners					
	Share capital	**Share premium**	**Other reserves**	**Foreign currency translation reserve**	**Accumulated deficit**	**Total**
	$'000	**$'000**	**$'000**	**$'000**	**$'000**	**$$'000**
	Note 8		**Note 10**			
At January 1, 2021	**871**	**5,430**	**-**	**200**	**(835)**	**5,666**
Loss for the period	-	-	-	-	(5,111)	(5,111)
Translation adjustment	-	-	-	(3,533)	-	(3,533)
Total comprehensive loss for the period	-	-	-	**(3,533)**	**(5,111)**	**(8,644)**
Share-based compensation expense	-	-	131	-	-	131
Corporate reorganization	(112)	112	-	-	-	-
Issue of share capital	542	285,906	-	-	-	286,448
Total transactions with owners	**430**	**286,018**	**131**	-	-	**286,579**
At September 30, 2021	**1,301**	**291,448**	**131**	**(3,333)**	**(5,946)**	**283,601**
At January 1, 2020	**801**	**-**	**-**	**(12)**	**(389)**	**400**
Loss for the period	-	-	-	-	(121)	**(121)**
Translation adjustment	-	-	-	15	-	15
Total comprehensive loss for the period	-	-	-	**15**	**(121)**	**(106)**
At September 30, 2020	**801**	**-**	**-**	**3**	**(510)**	**294**

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

GH RESEARCH PLC

Condensed consolidated interim statement of cash flows

	Nine months ended September 30,	
	2021	**2020**
	$'000	**$'000**
Cash flows from operating activities		
Loss for the period	**(5,111)**	**(121)**
Depreciation	10	-
Share-based compensation expense	131	-
Finance expense	9	-
Foreign exchange translation differences	(3,377)	-
Movement in working capital	(3,178)	(60)
Cash flows used in operating activities	**(11,516)**	**(181)**
Interest paid	(9)	-
Net cash used in operating activities	**(11,525)**	**(181)**
Cash flows used in investing activities		
Purchase of property, plant and equipment	(85)	-
Cash flows from financing activities		
Proceeds from capital contributions	309,200	-
Transaction costs from capital contributions	(22,582)	-
Net cash flows from financing activities	**286,618**	-
Net increase/(decrease) in cash	**275,008**	**(181)**
Cash at the beginning of the period	5,895	498
Impact of foreign exchange on cash	(158)	16
Cash at the end of the period	**280,745**	**333**

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

1. Corporate information

GH Research PLC (the "Company") was incorporated on March 29, 2021. The registered office of the Company is located at 28 Baggot Street Lower, Dublin 2, Ireland.

The Company and its subsidiary, GH Research Ireland Limited, (together the "Group" or "GH Research") are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Its initial focus is on developing the novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable 5-MeO-DMT product candidate, GH002, a proprietary injectable 5-MeO-DMT product candidate, and GH003, a proprietary intranasal 5-MeO-DMT product candidate.

On April 8, 2021, GH Research Ireland Limited issued 25,379,047 Series B preferred shares (which were redesignated into 10,151,618 ordinary shares of GH Research PLC prior to the closing of the initial public offering). The net proceeds of this issuance were $118.8 million, after deducting directly attributable transaction costs of $6.4 million.

On June 29, 2021, the Company completed an initial public offering ("IPO") on the Nasdaq Global Market ("Nasdaq") in which it issued and sold an aggregate of 11,499,999 ordinary shares at $16.00 per share, which included 1,499,999 ordinary shares issued and sold pursuant to the underwriters' exercise in full of their option to purchase additional ordinary shares. The net proceeds of the offering were $167.6 million, after deducting underwriting discounts and estimated directly attributable transaction costs of $16.4 million.

These unaudited condensed consolidated interim financial statements were presented to the board of directors and approved by them for issue on December 6, 2021.

2. Basis of preparation, significant judgments, and accounting policies

Basis of preparation

Compliance with International Financial Reporting Standards

The unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2021 have been prepared in accordance with IAS 34 "Interim Financial Reporting". The unaudited condensed consolidated interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the financial statements of GH Research Ireland Limited for the year ended December 31, 2020 which were prepared in accordance with International Financial Reporting Standards ("IFRS"). These unaudited condensed consolidated interim financial statements are presented in U.S. dollar ("USD" or "$"), which is the Company's functional currency and the Group's presentation currency.

The incorporation of GH Research PLC is accounted for as a capital reorganization and the comparatives are presented on that basis.

The financial information presented in this interim report does not represent full statutory accounts as defined by the Companies Act 2014. The statutory accounts of GH Research Ireland Limited for the year ended December 31, 2020, are expected to be filed with the Companies Registration Office by December 9, 2021. GH Research Ireland Limited was exempt from a statutory audit for the year ended December 31, 2020.

New and amended IFRS standards

There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2021, that are relevant to the Group and that have had any impact in the interim period. New standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Company as currently not relevant, are not listed here.

Going concern basis

GH Research is a clinical-stage biopharmaceutical company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. Research and development expenses have been incurred from the start of the Group's activities, generating negative cash flows from operating activities since formation.

Since its incorporation, the Group has funded its growth through capital increases. The Group has never taken bank loans nor otherwise incurred debt on its balance sheet. As a result, the Group is not exposed to liquidity risk through requests for early repayment of loans.

As of September 30, 2021, the Group's cash amounted to $280.7 million (December 31, 2020: $5.9 million).

The board of directors believes that the Group has sufficient financial resources available to cover its planned cash outflows for at least the next twelve months from the date of issuance of these unaudited condensed consolidated interim financial statements. The Group, therefore, continues to adopt the going concern basis in preparing its unaudited condensed consolidated interim financial statements.

Use of estimates and judgments

The preparation of the unaudited condensed consolidated interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing these unaudited condensed consolidated interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty included those that applied to the financial statements of GH Research Ireland Limited for the year ended December 31, 2020.

Accounting policies

The accounting policies, presentation and methods of computation followed in the unaudited condensed consolidated interim financial statements are consistent with those applied in the Group's most recent annual financial statements and have been applied consistently to all periods presented in the unaudited condensed consolidated interim financial statements.

Consolidation

The unaudited condensed consolidated interim financial statements incorporate the financial statements of the Company and its subsidiary, GH Research Ireland Limited. Subsidiaries are all entities over which the Company has control. Control is achieved when the Company has power over an entity, is exposed to or has rights to variable returns from its involvement with the entity and has the ability to affect returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date that control ceases. All intercompany transactions have been eliminated.

Foreign currency translation

The functional currency of the Company is the U.S. dollar given it is listed on NASDAQ and its fundraising activities are in U.S. dollars. The functional currency of its subsidiary, GH Research Ireland Limited, is euro due to its expenses being mainly incurred in euro. The condensed consolidated interim financial statements are presented in U.S. dollar which is the Group's presentation currency.

Items included in the financial statement of the Company's subsidiary are measured using the currency of the primary economic environment in which the entity operates which is the euro.

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the condensed consolidated interim statement of financial position date. The subsidiary is holding a U.S. cash balance and, as a result of the accounting treatment, when it is translated to euro in the subsidiary accounts, it results in a foreign currency translation difference in the income statement. On consolidation, the subsidiary's assets and liabilities in foreign currencies are retranslated and the resulting foreign currency difference goes through the foreign currency translation reserve.

Property, plant and equipment

Property, plant and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:

	Estimated Useful Life
IT equipment	3 years
Office equipment	3 years
Medical equipment	2 years

Share-based compensation expense

The fair value of options granted under the share option plan is recognized as a share-based compensation expense with a corresponding increase in equity. The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied.

Transaction costs

Incremental transaction costs are capitalized as incurred and are shown in equity as a deduction, net of tax, from the proceeds received from financing rounds and the initial public offering. If the equity instruments are not subsequently issued, the transaction costs would be expensed.

Cash

Cash represents cash held on bank current accounts and is carried at amortized cost. The Company's cash balance is maintained with well established, highly rated financial institutions. As of September 30, 2021, the cash balance is held at one bank that has S&P's credit rating of BBB+. The majority of the cash balance is held in U.S. dollars.

Fair value estimation

At September 30, 2021, the carrying amount is considered to be identical to the fair value for the following financial assets and liabilities:

- Cash
- Other current assets
- Trade payables and other current liabilities

Current and deferred income tax

Taxes on income are accrued in the same periods as the revenues and expenses to which they relate. Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. No current tax charge was recognized in the three and nine months ended 30 September 2021 and 2020, respectively, as no amount is expected to be payable or recoverable on the taxable results for those periods.

Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences or the unused tax losses can be utilized. Deferred income tax assets from tax credit carry-forwards are recognized to the extent that the national tax authority confirms the eligibility of such a claim and that the realization of the related tax benefit through future taxable profits is probable.

3. Segment information

Management considers the Group to have only a single segment: Research and Development ("R&D"). This is consistent with the way that information is reported internally within the Group for the purpose of allocating resources and assessing performance.

4. Research and development expense

During the three and nine months ended September 30, 2021 and 2020, the Company incurred research and development expenses as follows:

	Three months ended September 30,		Nine months ended September 30,	
	2021 $'000	2020 $'000	2021 $'000	2020 $'000
External costs	2,110	55	4,424	105
Employee expenses	441	-	770	-
Depreciation of property, plant and equipment	5	-	8	-
Total research and development expenses	**2,556**	**55**	**5,202**	**105**

The increase in external costs relates to the increase in technical development and clinical trial activity. The increase in employee expenses relates to the hiring of personnel in the research and development team to support the requirements of the increased clinical activities.

5. Other current assets

Other current assets primarily represent VAT receivable and prepayments.

6. Trade payables

Trade payables represents amounts incurred for transaction costs and the provision of manufacturing, research and consulting services which are outstanding at the end of the period.

7. Other current liabilities

Other current liabilities represent amounts accrued for transaction costs and the provision of manufacturing, research and consulting services.

8. Share capital

Issued and fully paid shares:	Number of outstanding shares	Share capital ($'000)	Share premium ($'000)
At December 31, 2020	**75,923,079**	**871**	**5,430**
Corporate reorganization and share consolidation	(45,553,847)	(112)	112
Issue of share capital	21,651,617	542	285,906
At September 30, 2021	**52,020,849**	**1,301**	**291,448**

The authorized share capital of GH Research PLC is 40,000,000,000 ordinary shares of nominal value $0.025 each.

(i) Incorporation

On March 29, 2021, GH Research PLC was incorporated with an authorized share capital of €25,000, divided into 25,000 A ordinary shares of nominal value €1.00 each. The sole subscriber to the incorporation constitution of GH Research PLC was Florian Schönharting who subscribed for 25,000 A ordinary shares of €1.00 each. The issuance and subsequent redemption is shown net within the issue of share capital.

(ii) Share issuance – Series B preferred shares

On April 8, 2021, GH Research Ireland Limited issued 25,379,047 Series B preferred shares (which were redesignated into 10,151,618 ordinary shares of GH Research PLC prior to the closing of the initial public offering). The net proceeds of this issuance were $118.8 million, after deducting directly attributable transaction costs of $6.4 million.

(iii) Share exchange

On May 27, 2021, as part of the corporate reorganization, all shareholders of GH Research Ireland Limited exchanged each of the shares held by them in GH Research Ireland Limited for shares of GH Research PLC of the same share classes with the same shareholders rights as the shares held by them in GH Research Ireland Limited, and as a result, GH Research Ireland Limited became a wholly owned subsidiary of GH Research PLC.

GH Research PLC issued the following shares:

- 70,000,000 ordinary shares, nominal value $0.01 each;
- 5,923,079 Series A preferred shares, nominal value $0.01 each; and
- 25,379,047 Series B preferred shares, nominal value $0.01 each.

(iv) Redemption of A Ordinary Shares

On June 24, 2021, GH Research PLC redeemed 25,000 A ordinary shares of €1.00 each at par and, following the redemption, cancelled the 25,000 A ordinary shares of €1.00 each. The redemption amount of €25,000 is included in “Other current liabilities” at September 30, 2021. The issuance and redemption is shown net within the issue of share capital.

(v) Conversion and share consolidation

On June 24, 2021, GH Research PLC (a) converted (i) 5,923,079 Series A preferred shares of nominal value $0.01 each into 5,923,079 ordinary shares of nominal value $0.01 each and (ii) 25,379,047 Series B preferred shares of nominal value $0.01 each into 25,379,047 ordinary shares of nominal value $0.01 each and (b) completed the 2.50-for-one share consolidation of the existing ordinary shares into an aggregate of 40,520,850 ordinary shares of nominal value $0.025 each.

(vi) Share issuance – IPO

On June 29, 2021, GH Research PLC closed its IPO of 11,499,999 ordinary shares on the Nasdaq Global Market at $16.00 per share. The net proceeds of the IPO were $167.6 million, after deducting underwriting discounts and estimated directly attributable transaction costs of $16.4 million.

9. Contingent liabilities and commitments

The Group has no contingent liabilities or material unavoidable commitments at the balance sheet date.

10. Share based compensation

Share Options

In June 2021, the Company adopted a share option plan referred to herein as the Share Option Plan under which grants of options are made to eligible participants. The Company has reserved 1,202,734 ordinary shares for future issuance under the Share Option Plan, which include ordinary shares pursuant to share-based equity awards issued to date. As of September 30, 2021, the Company has 1,058,354 ordinary shares available for the future issuance of share-based equity awards.

Under the Share Option Plan, any director (including our directors and directors of any other member of our group who are not active employees of the Company or any other company that is a member of our group) or employee of a member of the group or key consultant is eligible to be nominated by our remuneration committee to receive options.

The exercise price per share option is generally set by the Company at the fair market value at the date of grant. The awards generally vest 25% on the first anniversary of the date of grant, and thereafter evenly on a monthly basis over the subsequent three years in addition to a 2 year service condition. The contractual term (expiration) of each share option award granted is eight years from the date of grant.

Under the grant, the options may be settled only in ordinary shares of the Company. Therefore, the grants of share options under the Share Option Plan have been accounted for as equity-settled under IFRS 2. As such, the Company records a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the Company's unaudited condensed consolidated interim statement of comprehensive income and a corresponding increase to Other Reserves within equity on the unaudited condensed consolidated interim statement of financial position.

During the three and nine months ended September 30, 2021, the Company granted the option to purchase 86,597 and 137,084 ordinary shares, respectively, to employees which were in line with the general terms of the Share Option Plan as described above.

On September 24, 2021, the Company granted the option to purchase 7,296 ordinary shares to members of the board of directors which vested on the date of grant and are subject to a 2 year service condition with an exercise price of $2.05, as allowed by the Share Option Plan.

The following table summarizes the share option awards outstanding as of September 30, 2021:

	Average exercise price per share in USD	Number of awards	Weighted average remaining life in years
At December 31, 2020	-	-	-
Granted	14.83	144,380	7.84
At September 30, 2021	**14.83**	**144,380**	**7.84**

Awards outstanding as of September 30, 2021 expire through 2029. As of September 30, 2021, 7,296 awards are vested and generally subject to a 2 year service condition.

The weighted average grant date fair value of awards granted during three and nine months ended September 30, 2021 was $15.47 and $14.18, respectively, per award.

The fair values of the options granted were determined on the date of the grant using the Black-Scholes option-pricing model. The Company used an independent valuation firm to assist in calculating the fair value of the award grants per participant.

The fair values of the options granted during the three and nine months ended September 30, 2021 were determined on the date of the grant using the following assumptions:

	Three months ended September 30, 2021	Nine months ended September 30, 2021
Share price, in USD	20.56	15.00 - 20.56
Strike price, in USD – employees (weighted average)	20.83	17.70
Strike price, in USD – non-executive directors	2.05	2.05
Expected volatility	90% - 94%	90% - 95%
Award life (weighted average)	5.92	5.95
Expected dividends	-	-
Risk-free interest rate	0.97% - 1.12%	0.97% - 1.12%

The expected volatility was based on selected volatility determined by median values observed among other comparable public companies.

The award life is based on the time interval between the date of grant and the date during the eight-year life after which, when making the grant, the Company expected on average that participants would exercise their options.

As of September 30, 2021, the amount recorded as an increase to Other Reserves within equity on the unaudited condensed consolidated interim statement of financial position of the Share Option Plan was $131 thousand. The amount of expense for all awards recognized for services received during the three and nine months ended September 30, 2021 were $119 thousand and $131 thousand, respectively, and for the three and nine months ended September 30, 2020 were $nil.

11. Related party disclosures

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions.

On April 8, 2021, GH Research Ireland Limited issued 5,270,400 Series B preferred shares to directors and entities affiliated with directors.

On June 4, 2021, GH Research PLC granted the option to purchase 126,218 ordinary shares (which were redesignated into 50,487 ordinary shares prior to the closing of the IPO) to key management.

On June 24, 2021, GH Research PLC redeemed 25,000 A ordinary shares of €1.00 each at par and, following the redemption, cancelled the 25,000 A ordinary shares of €1.00 each, see note 8, “Share capital” for details.

On June 29, 2021, GH Research PLC issued 625,000 ordinary shares from the initial public offering to entities affiliated with directors.

12. Loss per share

The basic loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of shares in issue during the period as follows:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
Loss attributable to shareholders (in $’000)	(1,837)	(60)	(5,111)	(121)
Weighted average number of shares in issue[1]	52,020,849	28,000,000	40,912,190	28,000,000
Basic and diluted loss per share (in USD)	(0.035)	(0.002)	(0.125)	(0.004)

[1] Share data has been revised to give effect to the share conversion and share consolidation as explained in note 8, “Share capital”.

For the three and nine months ended September 30, 2021 and 2020, basic and diluted loss per share are calculated on the weighted average number of shares issued and outstanding and exclude shares to be issued under the Share Option Plan, as the effect of including those shares would be anti-dilutive.

13. Events after the reporting date

On December 6, 2021, the Company announced the successful outcome of the Phase 2 part of our Phase 1/2 clinical trial of GH001 in treatment-resistant depression (TRD), where the primary endpoint was met with 7 of 8 patients (87.5%) in remission (Montgomery–Åsberg Depression Rating Scale (MADRS) ≤10) at day 7 after dosing ($p<0.0001$).

Exhibit 99.2

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management's discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, as of and for the three and six months ended September 30, 2021. You should also read this discussion and analysis in conjunction with our audited consolidated financial statements, including the notes thereto, and the section titled "Risk Factors" included in our Registration Statement on Form F-1, as amended (Registration Nos. 333-256796 and 333-257371) (the "Registration Statement").

Our unaudited condensed consolidated interim financial statements were prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. The terms "dollar," "USD" or "$" refer to U.S. dollars. We have made rounding adjustments to some of the figures included in this discussion. Accordingly, any numerical discrepancies in any table between totals and sums of the amounts listed are due to rounding.

Unless otherwise indicated or the context otherwise requires, all references in this discussion and analysis to "GH Research" or "GH," the "Company," "we," "our," "ours," "us" or similar terms refer to GH Research PLC and its consolidated subsidiary.

Overview

We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Our initial focus is on developing our novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Our portfolio currently includes GH001, our proprietary inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, our proprietary injectable 5-MeO-DMT product candidate, and GH003, our proprietary intranasal 5-MeO-DMT product candidate. We have completed two Phase 1 healthy volunteer clinical trials (GH001-HV-101 and GH001-HV-103), in which administration of GH001 via inhalation was observed to be well tolerated at the investigated single dose levels and in an individualized dosing regimen with intra-subject dose escalation within a single day. We have also recently completed a Phase 1/2 clinical trial in patients with TRD (GH001-TRD-102). Based on observed clinical activity in the Phase 1 part of the clinical trial, we believe that administration of a single dose of GH001 has the potential to induce ultra-rapid remissions as measured by the Montgomery-Åsberg Depression Rating Scale, or MADRS, in certain patients, driven by the ultra-rapid onset of psychoactive effects (commonly within seconds) and an intense and short-lived (commonly five to 30 minutes) initial psychoactive experience. Based on observed clinical activity in the Phase 2 part of the trial, we believe that administration of an individualized dosing regimen with intra-subject dose escalation within a single day can further increase the MADRS remission rate as compared to a single dose of GH001.

We have incurred recurring operating losses since inception, including net losses of $5.1 million, $310 thousand and $446 thousand for the nine months ended September 30, 2021 and the years ended December 31, 2019 and 2020, respectively. As of September 30, 2021, we had an accumulated deficit of $5.9 million. We expect to incur significant expenses and operating losses for the foreseeable future as we expand our research and development activities. In addition, our losses from operations may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

- continue to develop and conduct clinical trials, including in expanded geographies such as the United States, for GH001, our inhalable 5-MeO-DMT product candidate, GH002, our injectable 5-MeO-DMT product candidate, and GH003, our intranasal 5-MeO-DMT product candidate for our initial indications and additional potential indications;

- continue both the technical development and expansion of our external manufacturing capabilities for our current product candidates GH001, GH002 and GH003 and of the medical devices required to deliver these product candidates;

- initiate and continue research and development, including nonclinical, clinical, and discovery efforts for any future product candidates;
- seek to identify additional product candidates;
- seek regulatory approvals for our product candidates GH001, GH002 and GH003 including the medical devices required to deliver these product candidates, or any other product candidates that successfully complete clinical development;
- add operational, financial and management information systems and personnel, including personnel to support our product candidate and device development and help us comply with our obligations as a public company;
- hire and retain additional personnel, such as clinical, quality control, scientific, commercial, sales, marketing and administrative personnel;
- continue to prepare, file, prosecute, maintain, protect and enforce our intellectual property rights and claims;
- establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the future to commercialize various products for which we may obtain regulatory approval;
- acquire or in-license other product candidates, medical devices to deliver our product candidates, and other technologies; and
- incur increased costs as a result of operating as a public company.

In addition, as we progress toward marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution.

As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of one or more of our product candidates or other research and development initiatives, which could have a material adverse effect on our business, results of operations, and financial condition. We will need to generate significant revenue to achieve profitability, and we may never do so.

We are subject to a number of risks comparable to those of other similar companies, including dependence on key individuals; the need to develop product candidates with the required safety and efficacy profile and which support regulatory approval and are commercially viable; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of our product candidates.

Business Updates

We announced the successful outcome of the Phase 2 part of our Phase 1/2 clinical trial of GH001 in treatment-resistant depression (TRD), where the primary endpoint was met with 7 of 8 patients (87.5%) in remission (Montgomery–Åsberg Depression Rating Scale (MADRS) ≤10) at day 7 after dosing ($p<0.0001$).

We plan to request a pre-IND meeting with the FDA and a Scientific Advice meeting with the EMA in the first quarter of 2022 and, pending the outcome of these meetings, we plan to initiate a multi-center, randomized, controlled Phase 2b trial of GH001 in TRD.

Given GH001's mechanism of action, we believe that GH001 may confer beneficial effects in other psychiatric and neurological disorders with unmet medical needs. We have recently initiated the development in two undisclosed psychiatric disorders which are expected to be announced in Q1 2022.

GH002, our 5-MeO-DMT product candidate formulated for administration via a proprietary injectable approach, and GH003, our recently added 5-MeO-DMT product candidate formulated for administration via a proprietary intranasal administration approach, are currently in preclinical development. We anticipate developing them in subpopulations and confined use scenarios within our focus area of psychiatric and neurological disorders.

COVID-19 Business Update

With the global spread of the ongoing COVID-19 pandemic in 2021, we have followed guidance issued by national and local governments to address and mitigate the impact of the COVID-19 pandemic on our employees and our business, including our nonclinical studies and clinical trials. We are focused on the health and safety of our employees, and have, among other things, implemented a work-from-home policy and eliminated nonessential business travel. While we are experiencing limited financial impacts at this time, the extent of the impact of the COVID-19 pandemic on our business, operations and development timelines and plans remains highly uncertain. The overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic as well as any economic slowdown as a result of the COVID-19 pandemic, could materially and adversely affect our business, financial condition and results of operations. We continue to closely monitor the COVID-19 pandemic as we evolve our business continuity plans, clinical development plans and response strategy.

In addition, our planned clinical trials have been and may continue to be affected by the COVID-19 pandemic, including (i) delays or difficulties in enrolling and retaining patients in our planned clinical trials, including patients that may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services; (ii) delays or difficulties in clinical site initiation, including difficulties in recruiting and retaining clinical site investigators and clinical site staff as well as closures of trial sites; (iii) diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, and because, who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations; (iv) interruption of our future clinical supply chain or key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal, state/provincial or municipal governments, employers and others; and (v) limitations in outsourced third-party resources that would otherwise be focused on the conduct of our planned clinical trials, including because of sickness of third-party personnel or their families, or the desire of third-party personnel to avoid contact with large groups of people.

Results of Operations

Comparison of the Three Months Ended September 30, 2021 and 2020

The following table summarizes our results of operations for the three months ended September 30, 2021 and 2020 (in thousands):

	Three Months Ended September 30		Change
	2021	2020	
Operating Expenses:			
Research and development	$ (2,556)	$ (55)	$ (2,501)
General and administrative	(2,110)	(5)	(2,105)
Loss from operations	(4,666)	(60)	(4,606)
Finance expense	(3)	—	(3)
Foreign currency translation differences	2,832	—	2,832
Loss for the period	$ (1,837)	$ (60)	$ (1,777)

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended September 30, 2021 and 2020 (in thousands):

	Three Months Ended September 30		Change
	2021	2020	
External costs	$ (2,110)	$ (55)	$ (2,055)
Employee expenses	(441)	—	(441)
Depreciation of property, plant and equipment	(5)	—	(5)
Research and development	$ (2,556)	$ (55)	$ (2,501)

Research and development expenses increased by $2.5 million from $55 thousand for the three months ended September 30, 2020, to $2.6 million for the three months ended September 30, 2021. The increase was primarily due to increased external costs relating to our technical developments and clinical trials and employee expenses relating to the hiring of personnel in our research and development team to support the requirements of increased clinical activities.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the three months ended September 30, 2021 and 2020 (in thousands):

	Three Months Ended September 30		Change
	2021	2020	
General and administrative	$ (2,110)	$ (5)	$ (2,105)

General and administrative expenses increased by $2.1 million from $5 thousand for the three months ended September 30, 2020, to $2.1 million for the three months ended September 30, 2021. The increase was primarily due to costs incurred in preparation for our initial public offering, as well as subsequent higher professional and compliance fees associated with being a public company, and increased employee expenses in our general and administrative functions to support our growth initiatives.

Finance expense

Our financial expense increased to $3 thousand for the three months ended September 30, 2021 from $nil for the three months ended September 30, 2020.

Foreign currency translation differences

Foreign currency translation gains increased to $2.8 million for the three months ended September 30, 2021, from $nil for the three months ended September 30, 2020. This increase was due to the translation of the U.S. dollar cash balance into euro in the accounts of our subsidiary, GH Research Ireland Limited, who's functional currency is euro. This resulted in a foreign currency translation gain.

Comparison of the Nine Months Ended September 30, 2021 and 2020

The following table summarizes our results of operations for the nine months ended September 30, 2021 and 2020 (in thousands):

	Nine Months Ended September 30		Change
	2021	2020	
Operating Expenses:			
Research and development	$ (5,202)	$ (105)	$ (5,097)
General and administrative	(3,277)	(16)	(3,261)
Loss from operations	(8,479)	(121)	(8,358)
Finance expense	(9)	—	(9)
Foreign currency translation differences	3,377	—	3,377
Loss for the period	$ (5,111)	$ (121)	$ (4,990)

Research and Development Expenses

The following table summarizes our research and development expenses for the nine months ended September 30, 2021 and 2020 (in thousands):

	Nine Months Ended September 30		Change
	2021	2020	
External costs	$ (4,424)	$ (105)	$ (4,319)
Employee expenses	(770)	—	(770)
Depreciation property, plant and equipment	(8)	—	(8)
Research and development	$ (5,202)	$ (105)	$ (5,097)

Research and development expenses increased by $5.1 million from $105 thousand for the nine months ended September 30, 2020, to $5.2 million for the nine months ended September 30, 2021. The increase was primarily due to increased external costs relating to our technical development and clinical trials and employee expenses relating to the hiring of personnel in our research and development team to support the requirements of increased clinical activities.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the nine months ended September 30, 2021 and 2020 (in thousands):

	Nine Months Ended September 30		Change
	2021	2020	
General and administrative	$ (3,277)	$ (16)	$ (3,261)

General and administrative expenses increased by $3.3 million from $16 thousand for the nine months ended September 30, 2020, to $3.3 million for the nine months ended September 30, 2021. The increase was primarily due to costs incurred in preparation for our initial public offering, as well as subsequent higher professional and compliance fees associated with being a public company, and increased employee expenses in our general and administrative functions to support our growth initiatives.

Finance expense

Our financial expense increased to $9 thousand for the nine months ended September 30, 2021 from $nil for the nine months ended September 30, 2020.

Foreign currency translation differences

Foreign currency translation gains increased to $3.4 million for the nine months ended September 30, 2021, from $nil for the nine months ended September 30, 2020. This increase was due to the translation of the U.S. dollar cash balance into euro in the accounts of our subsidiary, GH Research Ireland Limited, who's functional currency is euro. This resulted in a foreign currency translation gain.

Liquidity and Capital Resources

Sources of Liquidity

We have incurred operating losses since inception, and we have not generated any revenue from any product sales or any other sources. We have not yet commercialized any of our product candidates, which are in various phases of technical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. We have funded our operations to date primarily through equity financings, including our initial public offering. As of September 30, 2021, we had cash of $280.7 million.

In June 2021, we completed our initial public offering, in which we issued and sold an aggregate of 11,499,999 ordinary shares, including those issued and sold pursuant to the exercise in full of the underwriters' option to purchase additional ordinary shares. The net proceeds of the offering were $167.7 million, after deducting underwriting discounts and offering expenses payable by us.

In April 2021, we issued 25,379,047 Series B preferred shares (which were redesignated into 10,151,618 ordinary shares prior to the closing of the initial public offering). The net proceeds of this issuance were $118.8 million, after deducting estimated directly attributable transaction costs payable by us.

We plan to continue to fund our operating and capital funding needs through the net proceeds of our public offerings, additional equity financings and/or other forms of financing. We may also consider pursuing strategic partnerships for clinical development and commercialization of our product candidates.

Cash Flows

The following table provides information regarding our cash flows for the nine months ended September 30, 2021 and 2020, as well as for the years ended December 31, 2020 and 2019 (in thousands):

	Nine Months Ended September 30		Change	Year Ended December 31		Change
	2021	2020		2020	2019	
Net cash flows used in operating activities	$ (11,525)	$ (181)	$ (11,344)	$ (330)	$ (289)	$ (41)
Net cash flows used in investing activities	(85)	—	(85)	—	—	—
Net cash flows from financing activities	286,618	—	286,618	5,500	797	4,703
Net increase/(decrease) in cash	$ 275,008	$ (181)	$ 275,189	$ 5,170	$ 508	$ 4,662

Net Cash Flows Used in Operating Activities

Net cash flows used in operating activities increased to $11.5 million for the nine months ended September 30, 2021 from $181 thousand for the nine months ended September 30, 2020, an increase of $11.3 million. The increase was primarily due to a $5 million increase in loss for the period, a $3.4 million foreign exchange gain and $3.1 million related to changes in the components in working capital, including a $4.8 million increase in other current assets which primarily related to prepaid insurance costs, offset by a $1.7 million increase in trade payables and other current liabilities primarily related to an increase in clinical trial costs, technical development costs and legal and professional fees, primarily related to expenses associated with operating as a public company and other corporate activities as we continue to grow our business.

Net Cash Flows Used in Investing Activities

Net cash flows used in investing activities increased to $85 thousand for the nine months ended September 30, 2021 from $nil for the nine months ended September 30, 2020. The increase was due to purchase of property, plant and equipment.

Net Cash Flows from Financing Activities

Net cash flows from financing activities increased to $286.6 million for the nine months ended September 30, 2021 from $nil for the nine months ended September 30, 2020. The increase was due to the proceeds from the issuance of Series B preferred shares and our initial public offering.

Funding Requirements

We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we advance the technical development work, nonclinical studies and clinical trials of our product candidates and the medical devices required to deliver such product candidates. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. Accordingly, we expect to finance our cash needs through a combination of equity offerings, debt financings, convertible debt financings, strategic collaborations and licensing arrangements. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our future capital requirements will depend on many factors, which are outlined in our Registration Statement and this discussion and analysis.

Critical Accounting Policies and Significant Judgments and Estimates

There have been no material changes to the significant accounting policies and significant judgments and estimates from those described in the section in the Registration Statement titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” with the exception of the accounting for the share-based compensation expense as described in note 2, “Basis of preparation, significant judgments, and accounting policies” in the notes to our unaudited condensed consolidated interim financial statements.

Emerging Growth Company Status

On April 5, 2012, the JOBS Act was enacted. As an emerging growth company, or EGC, under the JOBS Act, we can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. This provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. This transition period is only applicable under U.S. GAAP. As a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required or permitted by the International Accounting Standards Board.

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we intend to continue to rely on certain of these exemptions, including without limitation, (i) providing an auditor's attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board, regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis.

We will remain classified as an EGC until the earlier of (1) the last day of the fiscal year (i) in which we have total annual gross revenue of $1.07 billion; (ii) following the fifth anniversary of the completion of our initial public offering; or (iii) in which we are deemed to be a "large accelerated filer," which requires the market value of our ordinary shares that is held by non-affiliates to exceed $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three-year period.

Recently Issued Accounting Pronouncements

As disclosed in note 2 to our unaudited condensed consolidated interim financial statements, there are no standards issued but not yet adopted which will have an impact on our unaudited condensed consolidated interim financial statements.

Cautionary Statement Regarding Forward-Looking Statements

This discussion contains statements that are, or may deemed to be, forward-looking statements. All statements other than statements of historical fact included in this discussion, including statements regarding our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and currently planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in this discussion can be identified by the use of forward-looking words such as ''may,'' ''anticipate,'' ''believe,'' ''could,'' ''expect,'' ''should,'' ''plan,'' ''intend,'' ''estimate,'' ''will,'' ''potential'' and ''ongoing,'' among others.

Forward-looking statements appear in a number of places in this discussion and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section in the Registration Statement titled ''Risk Factors''. These risks and uncertainties include, among others, factors relating to:

- the timing, progress and results of developing and conducting clinical trials for our GH001 and GH002 product candidates and the medical devices required to deliver these product candidates for our initial and potential additional indications;
- our efforts to expand into other jurisdictions such as the United States and in the European Union;
- our expectations related to the technical development and expansion of our external manufacturing capabilities for our GH001 and GH002 product candidates as well as the medical devices required to deliver these product candidates;
- our reliance on the success of our GH001 and GH002 product candidates;
- the timing, scope or likelihood of regulatory filings and approvals by the FDA, EMA or other comparable foreign regulatory authorities, for our GH001 and GH002 product candidates and our initial and potential additional indications;
- our expectations regarding the size of the eligible patient populations for our GH001 and GH002 product candidates, if approved for commercial use;
- our ability to identify third-party clinical sites to conduct trials and our ability to identify and train appropriately qualified therapists to administer our investigational therapy;
- the effect of the COVID-19 pandemic on aspects of our business or operations, including delays in the regulatory approval process, contracting with clinical sites and engaging in clinical trials;
- our ability to implement our business model and our strategic plans for our business and GH001 and GH002 product candidates;

- our ability to identify, develop or acquire and obtain approval by the FDA, EMA or other comparable foreign regulatory authorities of medical devices required to deliver our GH001 and GH002 product candidates;
- our commercialization and marketing capabilities and strategy;
- the effects of undesirable clinical trial outcomes and potential adverse public perception regarding the use of 5-MeO-DMT and psychedelics generally on the regulatory approval process and future development of our product;
- the pricing, coverage and reimbursement of our GH001 and GH002 product candidates, if approved;
- the scalability and commercial viability of our manufacturing methods and processes;
- the rate and degree of market acceptance and clinical utility of our GH001 and GH002 product candidates;
- our reliance on third-party suppliers for our nonclinical study and clinical trial drug substance and product candidate supplies, as well as key raw materials used in our manufacturing processes;
- our ability to establish or maintain collaborations or strategic relationships or obtain additional funding;
- our expectations regarding potential benefits of our GH001 and GH002 product candidates and our approach generally;
- our expectations around regulatory development paths and with respect to Controlled Substances Act designation;
- the scope of protection we and any current or future licensors or collaboration partners are able to establish and maintain for intellectual property rights covering our GH001 and GH002 product candidates;
- our ability to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights and proprietary technology of third parties;
- our ability to protect our intellectual property rights, including enforcing and defending intellectual property-related claims;
- regulatory developments in the United States, under the laws and regulations of the European Union and other jurisdictions;
- developments and projections relating to our competitors and our industry;
- our ability to remediate our material weaknesses in our internal control over financial reporting, as described in our Registration Statement;
- our expectations related to the use of proceeds from our initial public offering and the amount of time that our existing cash, together with the net proceeds from our initial public offering, will be sufficient to fund our operations and capital expenditures;
- our estimates regarding expenses, capital requirements and needs for additional financing;
- our ability to effectively manage our anticipated growth;
- our ability to attract and retain qualified employees and key personnel;
- whether we are classified as a Passive Foreign Investment Company for current and future periods;
- our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and as a foreign private issuer;
- the future trading price of the ordinary shares and impact of securities analysts' reports on these prices; and
- other risks and uncertainties, including those listed under the caption titled ''Risk Factors'' in the Registration Statement.

These forward-looking statements speak only as of the date of this discussion and are subject to a number of risks, uncertainties and assumptions described under the section in the Registration Statement titled ''Risk Factors'' and elsewhere in this discussion. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

In addition, statements that ‘‘we believe’’ and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this discussion, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

Exhibit 99.3

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

Dublin, Ireland, December 6, 2021 – GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2021 and gave updates on its business.

Third Quarter 2021 Financial Results

Cash position

Cash was $280.7 million as of September 30, 2021, compared to $5.9 million as of December 31, 2020.

Research and development expenses

R&D expenses were $2.6 million for the quarter ended September 30, 2021, compared to $55 thousand for the same quarter in 2020. The increase was primarily due to increased activities relating to our technical developments and clinical trials and increases in employee expenses to support these activities.

General and administrative expenses

G&A expenses were $2.1 million for the quarter ended September 30, 2021, compared to $5 thousand for the same quarter in 2020. The increase was primarily due to higher professional and compliance fees associated with being a public company, as well as increased employee expenses.

Net loss

Net loss was $1.8 million, or $0.035 loss per share, for the quarter ended September 30, 2021, compared to $60 thousand, or $0.002 loss per share, for the same quarter in 2020.

Business Updates

We announced today, in a separate press release, the successful outcome of the Phase 2 part of our Phase 1/2 clinical trial of GH001 in treatment-resistant depression (TRD), where the primary endpoint was met with 7 of 8 patients (87.5%) in remission (Montgomery–Åsberg Depression Rating Scale (MADRS) ≤10) at day 7 after dosing ($p<0.0001$).

We plan to request a pre-IND meeting with the FDA and a Scientific Advice meeting with the EMA in the first quarter of 2022 and, pending the outcome of these meetings, we plan to initiate a multi-center, randomized, controlled Phase 2b trial of GH001 in TRD.

Given GH001's mechanism of action, we believe that GH001 may confer beneficial effects in other psychiatric and neurological disorders with unmet medical needs. We have recently initiated the development in two undisclosed psychiatric disorders which are expected to be announced in Q1 2022.

GH002, our 5-MeO-DMT product candidate formulated for administration via a proprietary injectable approach, and GH003, our recently added 5-MeO-DMT product candidate formulated for administration via a proprietary intranasal administration approach, are currently in preclinical development. We anticipate developing them in subpopulations and confined use scenarios within our focus area of psychiatric and neurological disorders.

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with treatment-resistant depression (TRD).

About GH001

Our lead product candidate, GH001, is formulated for 5-MeO-DMT administration via a proprietary inhalation approach. With GH001, we have completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). Based on the observed clinical activity, where 87.5% of patients with TRD were brought into an ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has potential to change the way TRD is treated today. Across the GH001 program, no serious adverse events have been reported and GH001 was well tolerated at the investigated single dose levels and in the individualized dosing regimen.

About GH002 and GH003

GH002 is our 5-MeO-DMT product candidate formulated for administration via a proprietary injectable approach. GH003 is our 5-MeO-DMT product candidate formulated for administration via a proprietary intranasal administration approach. GH002 and GH003 are currently in preclinical development, and we anticipate developing them in subpopulations and confined use scenarios within our focus area of psychiatric and neurological disorders.

Forward-Looking Statements

This press release contains statements that are, or may deemed to be, forward-looking statements. All statements other than statements of historical fact included in this press release, including statements regarding our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and currently planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Relations:
Julie Ryan
GH Research PLC
investors@ghres.com

GH RESEARCH PLC

Condensed Consolidated Interim Statement of Comprehensive Income (Unaudited)

(in thousands, except share and per share amounts)

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
	$ '000	$ '000	$ '000	$ '000
Operating expenses				
Research and development	(2,556)	(55)	(5,202)	(105)
General and administration	(2,110)	(5)	(3,277)	(16)
Loss from operations	**(4,666)**	**(60)**	**(8,479)**	**(121)**
Finance expense	(3)	-	(9)	-
Foreign currency translation differences	2,832	-	3,377	-
Loss for the period	**(1,837)**	**(60)**	**(5,111)**	**(121)**
Other comprehensive income/(expense)				
Items that may be reclassified to profit or loss				
Currency translation adjustment	(2,845)	15	(3,533)	15
Total comprehensive loss for the period	**(4,682)**	**(45)**	**(8,644)**	**(106)**
Attributable to owners:				
Loss for the period	(1,837)	(60)	(5,111)	(121)
Comprehensive loss for the period	(2,845)	15	(3,533)	15
Loss per share				
Basic and diluted loss per share (in USD)	(0.035)	(0.002)	(0.125)	(0.004)

GH RESEARCH PLC

Condensed Consolidated Interim Statement of Financial Position

(in thousands)

	At September 30, 2021	At December 31, 2020
	$ '000	$ '000
ASSETS		
Current assets		
Cash	280,745	5,895
Other current assets	4,816	17
Total current assets	**285,561**	**5,912**
Non-current assets		
Property, plant and equipment	73	-
Total non-current assets	**73**	**-**
Total assets	**285,634**	**5,912**
LIABILITIES AND EQUITY		
Current liabilities		
Trade payables	1,214	1
Other current liabilities	819	245
Total current liabilities	**2,033**	**246**
Total liabilities	**2,033**	**246**
Equity attributable to owners		
Share capital	1,301	871
Share premium	291,448	5,430
Other reserves	131	-
Foreign currency translation reserve	(3,333)	200
Accumulated deficit	(5,946)	(835)
Total equity	**283,601**	**5,666**
Total liabilities and equity	**285,634**	**5,912**